JMP Securities Maintains Market Outperform on Sagimet Biosciences, Raises Price Target to $47
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has maintained a Market Outperform rating on Sagimet Biosciences (NASDAQ:SGMT) and increased the price target from $31 to $47, indicating a positive outlook on the company's stock.
January 23, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities analyst has reaffirmed Sagimet Biosciences with a Market Outperform rating and raised the price target to $47, suggesting a bullish stance on the stock.
The increase in price target by a reputable analyst typically signals a strong conviction in the company's future performance and growth potential. This can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100